Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. Matthew Brams presented new data showing the efficacy of CTx-1301 for ADHD.
Bringing researchers in attention deficit/hyperactivity disorder (ADHD) is crucial in the pursuit of new treatments and updated standards of care.
Unlike other psychiatry conferences where ADHD makes up only a portion of the agenda, during the American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference ADHD is the main focus.
Researchers from across the globe logged on to the virtual conference to share data and antidotes on ADHD and related diseases like autism and bipolar disorder.
One such researcher was Matthew Brams, MD, Chief Medical Officer of Cingulate Therapeutics, who presented new data from a phase 2 trial testing CTx-1301 as a viable treatment for adults with ADHD.
Brams explained in an interview with HCPLive®, the value of a conference and organization solely focusing on ADHD. He said ADHD is 1 of the most prolific and primary psychiatric diagnosis.
He also said providers have a chance to network with researchers in an intimate setting where everyone has a similar focus.
Brams also said another benefit of APSARD is the organization will work with the US Food and Drug Administration (FDA) and other regulation bodies overseas to promote advocacy for ADHD treatment and care, which is something the larger organizations don’t do as well.